[go: up one dir, main page]

MX2021015054A - Agonista de pd-1 y metodo para usar el mismo. - Google Patents

Agonista de pd-1 y metodo para usar el mismo.

Info

Publication number
MX2021015054A
MX2021015054A MX2021015054A MX2021015054A MX2021015054A MX 2021015054 A MX2021015054 A MX 2021015054A MX 2021015054 A MX2021015054 A MX 2021015054A MX 2021015054 A MX2021015054 A MX 2021015054A MX 2021015054 A MX2021015054 A MX 2021015054A
Authority
MX
Mexico
Prior art keywords
same
agonist
chain polypeptide
making
methods
Prior art date
Application number
MX2021015054A
Other languages
English (en)
Inventor
Marilyn Kehry
Stephen Parmley
Robert P Morse
Gregory N Gold
Janean Fisher
Martin Edward Dahl
Margaret Habash Marino
Rupal Kalapanda
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of MX2021015054A publication Critical patent/MX2021015054A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un agente de unión a PD-1 que comprende un polipéptido de cadena pesada de inmunoglobulina y un polipéptido de cadena ligera de inmunoglobulina, así como composiciones y métodos relacionados para preparar y usar los mismos.
MX2021015054A 2019-06-05 2020-06-04 Agonista de pd-1 y metodo para usar el mismo. MX2021015054A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962857699P 2019-06-05 2019-06-05
US201962863193P 2019-06-18 2019-06-18
US202062983512P 2020-02-28 2020-02-28
PCT/US2020/036143 WO2020247648A2 (en) 2019-06-05 2020-06-04 Pd-1 agonist and method of using same

Publications (1)

Publication Number Publication Date
MX2021015054A true MX2021015054A (es) 2022-03-17

Family

ID=71895175

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015054A MX2021015054A (es) 2019-06-05 2020-06-04 Agonista de pd-1 y metodo para usar el mismo.

Country Status (12)

Country Link
US (1) US20220235132A1 (es)
EP (1) EP3980460A2 (es)
JP (3) JP7490679B2 (es)
KR (2) KR20220016925A (es)
CN (1) CN114364697A (es)
AU (2) AU2020286444B2 (es)
BR (1) BR112021024507A2 (es)
CA (1) CA3142714A1 (es)
IL (1) IL288361A (es)
MX (1) MX2021015054A (es)
TW (1) TW202112815A (es)
WO (1) WO2020247648A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7512433B2 (ja) 2020-05-26 2024-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｐｄ－１抗体
WO2022239820A1 (ja) 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物
JP2024539457A (ja) * 2021-11-19 2024-10-28 ミロバイオ・リミテッド 操作されたｐｄ－１抗体及びその使用
JP2026503178A (ja) 2022-10-25 2026-01-28 サイズミック セラピューティク インコーポレイテッド バリアントＩｇＧ ＦＣポリペプチド及びその使用
CN120424213A (zh) * 2024-02-02 2025-08-05 英诺湖医药(杭州)有限公司 特异性结合pd-1的单克隆抗体及其医药用途
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
WO2008103474A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Methods of generating libraries and uses thereof
US9181342B2 (en) * 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies

Also Published As

Publication number Publication date
BR112021024507A2 (pt) 2022-03-08
WO2020247648A3 (en) 2021-01-14
KR20250126805A (ko) 2025-08-25
JP2022534803A (ja) 2022-08-03
CA3142714A1 (en) 2020-12-10
AU2020286444B2 (en) 2025-02-06
JP2025134780A (ja) 2025-09-17
TW202112815A (zh) 2021-04-01
US20220235132A1 (en) 2022-07-28
KR20220016925A (ko) 2022-02-10
AU2025203103A1 (en) 2025-05-29
WO2020247648A2 (en) 2020-12-10
AU2020286444A1 (en) 2021-12-23
CN114364697A (zh) 2022-04-15
JP2024119816A (ja) 2024-09-03
IL288361A (en) 2022-01-01
JP7697106B2 (ja) 2025-06-23
JP7490679B2 (ja) 2024-05-27
EP3980460A2 (en) 2022-04-13
NZ782673A (en) 2025-08-29

Similar Documents

Publication Publication Date Title
MX2021015054A (es) Agonista de pd-1 y metodo para usar el mismo.
DOP2025000309A (es) Compuestos moduladores de glp-1r
CL2021003373A1 (es) Nuevos inhibidores de egfr
CL2020003361S1 (es) Cargador.
CL2020003360S1 (es) Cargador.
CL2020000595S1 (es) Estuche de auriculares.
CL2019002792A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo.
CL2018002533A1 (es) Procedimientos para el tratamiento de la depresíón usando antagonisdas de los receptores de orexina-2.
MX2019008092A (es) Metodo para acceso aleatorio y dispositivo terminal.
CL2019002232S1 (es) Automóvil.
MX2019012352A (es) Composiciones, sistemas, kits y metodos para ablacion neural.
MX389499B (es) Metodos, composiciones y usos relacionados con los mismos
CL2020001201S1 (es) Automóvil.
MX2021014853A (es) Variante de proteina de exportacion de l-treonina y procedimiento para la produccion de l-treonina mediante el uso de la misma.
CL2019002797A1 (es) Preservantes para madera.
AR117565A1 (es) Agentes de unión a c3 y método de uso de los mismos
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
DE112020005499A5 (de) Arbeitszylinder
AR119677A1 (es) Dominios de unión anti-cd38
UY38385A (es) Concentrado y aislado de cannabinoide, método para su obtención y uso
CO2022009062A2 (es) Composición para la preparación de alulosa y procedimiento para la preparación de alulosa mediante el uso de la misma
AR102573A1 (es) Aditivos depuradores de sulfuro sinérgico para usar en operaciones en yacimientos de petróleo
MX380530B (es) Combinación de herbicida.
CU20220019A7 (es) Proteínas de fusión nkg2d
CL2021002423A1 (es) Un novedoso compuesto derivado de alulosa